BPG is committed to discovery and dissemination of knowledge
Case Report
Copyright ©The Author(s) 2026.
World J Gastroenterol. Jan 28, 2026; 32(4): 114906
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.114906
Table 1 Laboratory parameters and medications during hospitalization
ParameterTime to treatment initiation (days)
D - 0
D + 1
D + 2
D + 3
D + 4
D + 5
D + 6
D + 7
D + 8
D + 13
D + 15
CDT with urokinase (U/hour)120001200012000140001600016000160001200010000Off
Systemic anticoagulant
    Heparin pump (U/hour)440440320320200Off
    Oral apixaban2.5 mg twice/day
Fibrinogen (mg/dL)684501624624551342460668
APTT (second)32.844.938.235.939.641.541.336.045.539.8
Lactate (mmol/L)2.22.51.61.00.70.9
CK (U/L)57472201957648
WBC (103/μL)124801418012030108301072089801111091408570
Hemoglobin (g/dL)18.817.013.713.513.412.413.711.111.4
CRP (mg/dL)11.1010.581.773.854.30
ImagingAbdominal CTVenographyVenography
Table 2 Clinical and therapeutic parameters of portal vein thrombolysis, including the catheter access method, recanalization, and complication rate
Ref.CaseMPD (%)Total occlusive PVTCDT timing (day)CDT
Complete recanalization rate, AC/CDT (%)Failure rate, AC/CDT (%)Bleeding complications[13]
Transhepatic approach
TIPS
Grade 1/2, AC/CDT (%)
Grade 3/4, AC/CDT (%)
Death, AC/CDT (%)
Rössle et al[7], 20206523528.93530.0/54.015.0/14.30/22.50/2.50/0
Benmassaoud et al[8], 20192222.71741113.7/70.063.6/9.1Total 3180/18.10/0
Wu et al[9], 2025251218625-/48-/16-/160/00/0
Klinger et al[10], 20172920.716717-/52.9-/11.8-/5.9-/0-/0
Mansour et al[11], 20222114.31413912-/35.09.5-/23.8-/19.0-/1.0
Gerwing et al[12], 2019805062-/62.5-/12.5-/12.5-/37.5-/1.0